Paula Gonzalez-Jimenez

Mrs. Paula Gonzalez-Jimenez

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Infection
Verified
Journal Article
Closed access
PDF file
ETEva Tabernero
Eva Tabernero
LRLuis A. Ruiz
Luis A. Ruiz
PEPedro Pablo España
Pedro Pablo España
RMRaúl Méndez
Raúl Méndez
LSLeyre Serrano
Leyre Serrano
RZRafael Zalacain
Rafael Zalacain

Verified
Journal Article
Open access
PDF file
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RMRaúl Méndez
Raúl Méndez
ALAna Latorre
Ana Latorre
MPMONICA PIQUERAS
MONICA PIQUERAS
MBMaría Nieves Balaguer-Cartagena
María Nieves Balaguer-Cartagena
RMRosario Menéndez
Rosario Menéndez
The role of NETs and platelet activation in COVID-19 is scarcely known. We aimed to evaluate the role of NETs (citrullinated histone H3 [CitH3], cell-free DNA [cfDNA]) and platelet activation markers (soluble CD40 ligand [CD40L] and P-selectin) in estimating the hazard of different clinical trajectories in patients with COVID-19. We performed a prospective study of 204 patients, categorized as outpatient, hospitalized and ICU-admitted. A multistate model was designed to estimate probabilities of clinical transitions across varying states, such as emergency department (ED) visit, discharge (outpatient), ward admission, ICU admission and death. Levels of cfDNA, CitH3 and P-selectin were associated with the severity of presentation and analytical parameters. The model showed an increased risk of higher levels of CitH3 and P-selectin for ED-to-ICU transitions (Hazard Ratio [HR]: 1.35 and 1.31, respectively), as well as an elevated risk of higher levels of P-selectin for ward-to-death transitions (HR: 1.09). Elevated levels of CitH3 (HR: 0.90), cfDNA (HR: 0.84) and P-selectin (HR: 0.91) decreased the probability of ward-to-discharge transitions. A similar trend existed for elevated levels of P-selectin and ICU-to-ward transitions (HR 0.40); In conclusion, increased NET and P-selectin levels are associated with more severe episodes and can prove useful in estimating different clinical trajectories.

18 November 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LSLeyre Serrano
Leyre Serrano
LILuis Alberto Ruiz Iturriaga
Luis Alberto Ruiz Iturriaga
PEPedro Pablo España
Pedro Pablo España
RMRaúl Méndez
Raúl Méndez
SFSilvia Pérez Fernández
Silvia Pérez Fernández
RJRafael Zalacain Jorge
Rafael Zalacain Jorge
To analyse differences in clinical presentation and outcome between bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) and sSvere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pneumonia. This observational multi-centre study was conducted on patients hospitalized with B-PCAP between 2000 and 2020 and SARS-CoV-2 pneumonia in 2020. Thirty-day survival, predictors of mortality, and intensive care unit (ICU) admission were compared. In total, 663 patients with B-PCAP and 1561 patients with SARS-CoV-2 pneumonia were included in this study. Patients with B-PCAP had more severe disease, a higher ICU admission rate and more complications. Patients with SARS-CoV-2 pneumonia had higher in-hospital mortality (10.8% vs 6.8%; P=0.004). Among patients admitted to the ICU, the need for invasive mechanical ventilation (69.7% vs 36.2%; P<0.001) and mortality were higher in patients with SARS-CoV-2 pneumonia. In patients with B-PCAP, the predictive model found associations between mortality and systemic complications (hyponatraemia, septic shock and neurological complications), lower respiratory reserve and tachypnoea; chest pain and purulent sputum were protective factors in these patients. In patients with SARS-CoV-2 pneumonia, mortality was associated with previous liver and cardiac disease, advanced age, altered mental status, tachypnoea, hypoxaemia, bilateral involvement, pleural effusion, septic shock, neutrophilia and high blood urea nitrogen; in contrast, ≥7 days of symptoms was a protective factor in these patients. In-hospital mortality occurred earlier in patients with B-PCAP. Although B-PCAP was associated with more severe disease and a higher ICU admission rate, the mortality rate was higher for SARS-CoV-2 pneumonia and deaths occurred later. New prognostic scales and more effective treatments are needed for patients with SARS-CoV-2 pneumonia.

Verified
Journal Article
Open access
PDF file
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RMRaúl Méndez
Raúl Méndez
ALAna Latorre
Ana Latorre
NMNoé Mengot
Noé Mengot
MPMONICA PIQUERAS
MONICA PIQUERAS
RMRosario Menéndez
Rosario Menéndez
COVID-19 has been a diagnostic and therapeutic challenge. It has marked a paradigm shift when considering other types of pneumonia etiology. We analyzed the biomarkers related to endothelial damage and immunothrombosis in COVID-19 in comparison to community-acquired pneumonia (CAP) through a case–control study of 358 patients with pneumonia (179 hospitalized with COVID-19 vs. 179 matched hospitalized with CAP). Endothelial damage markers (endothelin and proadrenomedullin), neutrophil extracellular traps (NETs) (citrullinated-3 histone, cell-free DNA), and platelet activation (soluble P-selectin) were measured. In-hospital and 1-year follow-up outcomes were evaluated. Endothelial damage, platelet activation, and NET biomarkers are significantly higher in CAP compared to COVID-19. In-hospital mortality in COVID-19 was higher compared to CAP whereas 1-year mortality and cardiovascular complications were higher in CAP. In the univariate analysis (OR 95% CIs), proADM and endothelin were associated with in-hospital mortality (proADM: CAP 3.210 [1.698–6.070], COVID-19 8.977 [3.413–23.609]; endothelin: CAP 1.014 [1.006–1.022], COVID-19 1.024 [1.014–1.034]), in-hospital CVE (proADM: CAP 1.623 [1.080–2.439], COVID-19 2.146 [1.186–3.882]; endothelin: CAP 1.005 [1.000–1.010], COVID-19 1.010 [1.003–1.018]), and 1-year mortality (proADM: CAP 2.590 [1.644–4.080], COVID-19 13.562 [4.872–37.751]; endothelin: CAP 1.008 [1.003–1.013], COVID-19 1.026 [1.016–1.037]). In conclusion, COVID-19 and CAP showed different expressions of endothelial damage and NETs. ProADM and endothelin are associated with short- and long-term mortality.

22 April 2022 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RMRaúl Méndez
Raúl Méndez
ALAna Latorre
Ana Latorre

21 May 2022 in Chest
Verified
Journal Article
Closed access
RMRosario Menéndez
Rosario Menéndez
RMRaúl Méndez
Raúl Méndez
PGPaula Gonzalez-Jimenez
Paula Gonzalez-Jimenez
RZRafael Zalacain
Rafael Zalacain
LRLuis A. Ruiz
Luis A. Ruiz
ATAntoni Torres
Antoni Torres